Projects per year
Personal profile
Area of Expertise
Dr. Dong’s research interests include pharmaceutical analysis/bioanalysis, drug formulation, and delivery. She develops novel formulation nanotechnologies to improve bioavailability of oral drugs and deliver macromolecules such as siRNAs and proteins. In addition to novel drug formulations, her lab evaluates these formulations for therapeutic efficacy (e.g. anticancer drugs), pharmacokinetics, and biodistribution. Thus, her lab has the capacity to perform bioassays for both small molecules and macromolecules. Additionally, she collaborates with the clinical pharmacy to test stability of compounding medications and Y-site compatibility.
Education/Academic qualification
BS in Industrial Analysis
MS in Applied Chemistry, East China University of Science and Technology
PhD in Pharmaceutical Sciences, University of Kentucky
Fingerprint
Dive into the research topics where Xiaowei Dong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
-
Novel Formulation Technology to Enhance Oral Absorption of Water-insoluble Drugs
1/07/20 → 30/06/21
Project: Research
-
Nanoparticle Drug Delivery to Overcome Multidrug Resistance to Cancer
1/04/14 → 31/08/15
Project: Research
-
Nerve Growth Factor Nanoparticles to Cross the Blood-Brain Barrier
NINDS: Neurological Disorders & Stroke
1/02/14 → 31/01/17
Project: Research
-
Nerve Growth Factor Nanoparticles to Cross the Blood-Brain Barrier
Dong, X. & Dong, X.
1/02/14 → 31/01/17
Project: Research
Research Output
-
Curcumin nanoparticles and their cytotoxicity in docetaxel-resistant castration-resistant prostate cancer cells
Tanaudommongkon, I., Tanaudommongkon, A., Prathipati, P., Nguyen, J. T., Keller, E. T. & Dong, X., Aug 2020, In: Biomedicines. 8, 8, 253.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Determination of metformin bio-distribution by LC-MS/MS in mice treated with a clinically relevant paradigm
Chaudhari, K., Wang, J., Xu, Y., Winters, A., Wang, L., Dong, X., Cheng, E. Y., Liu, R. & Yang, S. H., Jun 2020, In: PLoS ONE. 15, 6, e0234571.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Quantitative measurements of IR780 in formulations and tissues
Wang, J., Zhang, J., Nguyen, N. T. D., Chen, Y. A., Hsieh, J. T. & Dong, X., 5 Feb 2021, In: Journal of Pharmaceutical and Biomedical Analysis. 194, 113780.Research output: Contribution to journal › Article › peer-review
-
Current strategies for brain drug delivery
Dong, X., 2018, In: Theranostics. 8, 6, p. 1481-1493 13 p.Research output: Contribution to journal › Review article › peer-review
183 Scopus citations -
Development and characterization of docetaxel-loaded nanoparticles for docetaxel-resistant castration-resistant prostate cancer
Tanaudommongkon, A., Tanaudommongkon, I., Prathipati, P., Nguyen, J. & Dong, X., 1 Jan 2017, In: Journal of Nanoscience and Nanotechnology. 17, 6, p. 3920-3926 7 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations